Jennison Associates’s Regulus Therapeutics RGLS Stock Holding History

Jennison Associates’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-3,395	Closed	-$4.46M	–	759
2015 Q2	$4.46M	Buy	3,395 +34	+1%	+$54.9K	﹤0.01%	546
2015 Q1	$6.83M	Buy	3,361 +10	+0.3%	+$21.7K	0.01%	507
2014 Q4	$6.45M	Buy	3,351 +658	+24%	+$1.17M	0.01%	500
2014 Q3	$2.21M	Buy	2,693 +4	+0.1%	+$3.38K	﹤0.01%	574
2014 Q2	$2.6M	Sell	2,689 -316	-11%	-$271K	﹤0.01%	552
2014 Q1	$3.25M	Buy	3,005 +10	+0.3%	+$11.1K	﹤0.01%	551
2013 Q4	$2.66M	Buy	2,995 +12	+0.4%	+$10.3K	﹤0.01%	549
2013 Q3	$3.38M	Buy	+2,983	New	+$3.52M	﹤0.01%	527

Other funds holding RGLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jennison Associates's RGLS Position: Q3 2015 in Review

Jennison Associates sold out of Regulus Therapeutics (RGLS) in Q3 2015, closing a stake of 3,395 shares — an estimated $4.46M sold.

Jennison Associates first reported a position in RGLS in Q3 2013 and held it in 8 quarters. The position peaked at $6.83M in Q1 2015. 92 funds tracked by Wall St. Rank hold RGLS as of Q3 2015.

Jennison Associates reported no remaining Regulus Therapeutics position as of Q3 2015 after selling out during the quarter.
Jennison Associates sold 3,395 Regulus Therapeutics shares in Q3 2015, an estimated $4.46M.
Jennison Associates first reported a position in Regulus Therapeutics in Q3 2013 and held it in 8 quarters.
Jennison Associates's Regulus Therapeutics position peaked at $6.83M in Q1 2015.
92 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2015.

Based on Jennison Associates's 13F filing for Q3 2015, filed 6 Nov 2015.